Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

被引：9
|
作者：
Opat, Stephen
Tedeschi, Alessandra
Linton, Kim
McKay, Pamela
Hu, Bei
Chan, Henry
Jin, Jie
Zinzani, Pier Luigi
Browett, Peter
Coleman, Morton
Sobieraj-Teague, Magdalena
Ke, Xiaoyan
Sun, Mingyuan
Marcus, Robert
Portell, Craig A.
Zhou, Keshu
Thieblemont, Catherine
Co, Melannie
Wang, Weige
Tankersley, Chris
Zhou, Wenxiao
Cappellini, Massimo
Huang, Jane
Trotman, Judith
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134611
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): Final analysis of MAGNOLIA (BGB-3111-214)
    Linton, Kim M.
    Trotman, Judith
    Mckay, Pamela
    Ardeshna, Kirit
    Iyengar, Sunil
    Tedeschi, Alessandra
    Hu, Bei
    Leitch, Sophie
    Jin, Jie
    Sun, Mingyuan
    Sobieraj-Teague, Magdalena
    Zinzani, Pier Luigi
    Browett, Peter
    Ke, Xiaoyan
    Portell, Craig A.
    Thieblemont, Catherine
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza A.
    Ho, Shir-Jing
    Zhou, Keshu
    Liang, Zhiyu
    Xu, Jianfeng
    Tankersley, Chris
    Delarue, Richard
    Co, Melannie
    Opat, Stephen
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 12 - 12
  • [2] Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
    Opat, Stephen
    Tedeschi, Alessandra
    Hu, Bei
    Linton, Kim M.
    McKay, Pamela
    Chan, Henry
    Jin, Jie
    Sun, Mingyuan
    Sobieraj-Teague, Magdalena
    Zinzani, Pier Luigi
    Browett, Peter J.
    Ke, Xiaoyan
    Portell, Craig A.
    Thieblemont, Catherine
    Ardeshna, Kirit
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza
    Ho, Shir-Jing
    Zhou, Keshu
    Liang, Zhiyu
    Xu, Jianfeng
    Tankersley, Chris
    Delarue, Richard
    Co, Melannie
    Trotman, Judith
    BLOOD, 2022, 140
  • [3] Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma
    Opat, Stephen
    Marcus, Robert
    Portell, Craig A.
    Reed, William
    Tankersley, Chris
    Huang, Jane
    Trotman, Judith
    BLOOD, 2019, 134
  • [4] Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (SUPPL 6) : 137 - 137
  • [5] SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)
    Tedeschi, A.
    Trotman, J.
    Zinzani, P.
    Cavallo, F.
    Marasca, R.
    Liberati, A.
    Linton, K.
    Mckay, P.
    Hu, B.
    Coleman, M.
    Ardeshna, K.
    Bijou, F.
    Marcus, R.
    Portell, C.
    Thieblemont, C.
    Bachy, E.
    Costello, R.
    Iyengar, S.
    Mocikova, H.
    Co, M.
    Li, X.
    Zhou, W.
    Cappellini, M.
    Tankersley, C.
    Huang, J.
    Opat, S.
    HAEMATOLOGICA, 2021, 106 (10) : 35 - 35
  • [6] Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
    Opat, Stephen
    Tedeschi, Alessandra
    Hu, Bei
    Linton, Kim M.
    Mckay, Pamela
    Leitch, Sophie
    Coleman, Morton
    Zinzani, Pier Luigi
    Jin, Jie
    Sun, Mingyuan
    Sobieraj-Teague, Magdalena
    Browett, Peter
    Ke, Xiaoyan
    Thieblemont, Catherine
    Ardeshna, Kirit
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza A.
    Ho, Shir-Jing
    Zhou, Keshu
    Liang, Zhiyu
    Xu, Jianfeng
    Tankersley, Chris
    Delarue, Richard
    Co, Melannie
    Trotman, Judith
    BLOOD ADVANCES, 2023, 7 (22) : 6801 - 6811
  • [7] Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).
    Opat, Stephen
    Marcus, Robert
    Portell, Craig Anthony
    Reed, William
    Co, Melannie
    Huang, Jane
    Trotman, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
    Opat, Stephen
    Tedeschi, Alessandra
    Linton, Kim
    McKay, Pamela
    Hu, Bei
    Chan, Henry
    Jin, Jie
    Sobieraj-Teague, Magdalena
    Zinzani, Pier Luigi
    Coleman, Morton
    Thieblemont, Catherine
    Browett, Peter
    Ke, Xiaoyan
    Sun, Mingyuan
    Marcus, Robert
    Portell, Craig A.
    Ardeshna, Kirit
    Bijou, Fontanet
    Walker, Patricia
    Hawkes, Eliza A.
    Mapp, Sally
    Ho, Shir-Jing
    Talaulikar, Dipti
    Zhou, Ke-Shu
    Co, Melannie
    Li, Xiaotong
    Zhou, Wenxiao
    Cappellini, Massimo
    Tankersley, Chris
    Huang, Jane
    Trotman, Judith
    CLINICAL CANCER RESEARCH, 2021, 27 (23) : 6323 - 6332
  • [9] Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma
    Panayiotidis, Panayiotis
    Follows, George A.
    Mollica, Luigina
    Nagler, Arnon
    Ozcan, Muhit
    Santoro, Armando
    Stevens, Don
    Trevarthen, David
    Hiemeyer, Florian
    Garcia-Vargas, Jose
    Childs, Barrett H.
    Zinzani, Pier Luigi
    Dreyling, Martin
    BLOOD ADVANCES, 2021, 5 (03) : 823 - 828
  • [10] Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma
    Thieblemont, Catherine
    Wahlin, Bjorn E.
    Mohseninejad, Leyla
    Wang, Kaijun
    Zhang, Ina
    Keeping, Sam
    Yang, Keri
    Zinzani, Pier L.
    LEUKEMIA & LYMPHOMA, 2025, 66 (02) : 240 - 249
12345